- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03113760
Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency
February 1, 2024 updated by: AB2 Bio Ltd.
Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial With Tadekinig Alfa (r-hIL-18BP) in Patients With IL-18 Driven Monogenic Autoinflammatory Conditions: NLRC4 Mutation and XIAP Deficiency
This is a Phase 3 study to assess the safety and efficacy of Tadekinig alfa in patients with monogenic, interleukin-18 (IL 18) driven autoinflammation due to Nucleotide-binding oligomerization domain, leucine-rich repeat and caspase recruiting domain (CARD domain) containing 4 (NLRC4) - Macrophage activation syndrome (MAS) mutation (NLRC4-MAS mutation) or X-linked inhibitor of apoptosis (XIAP) deficiency.
Because of the likelihood for pathogenic IL-18 in certain monogenic diseases, patients known to harbor deleterious mutations in NLRC4-MAS or XIAP and who have a history of ongoing inflammation will be enrolled if they have ferritin ≥ 500 ng/mL or persistent C reactive protein (CRP) elevation ≥ 2 times the upper limit of normal (ULN) and the patients should have a Modified Autoinflammatory Disease Activity Index (mAIDAI) ≥ 4.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is designed with single-arm, open-label phase (SAOL) of Tadekinig alfa treatment duration for 18-week followed by an up to 16-week Randomized Withdrawal (RW) period for efficacy and safety evaluation, with no interruption between the two phases of treatment.
The screening period will occur before the SAOL phase and before the first dose of Investigational Medicinal Product (IMP)
Study Type
Interventional
Enrollment (Actual)
15
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, ON M5G 1X8
- The Hospital for Sick Children
-
-
Providence
-
Montréal, Providence, Canada, QC H3T 1C5
- CHU Sainte-Justine
-
-
-
-
Baden-Württemberg
-
Freiburg, Baden-Württemberg, Germany, 79106
- Universitätsklinikum Freiburg, Centrum für Chronische Immundefizienz (CCI) - Paediatric Unit
-
-
-
-
California
-
La Jolla, California, United States, 92056
- UCSD _ Department of Pediatrics / Rady Children's Hospital
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Children's Healthcare of Atlanta at Egleston
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati Children's Hospital Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Children Hospital of Philadelphia
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital _ Baylor College of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
INCLUSION CRITERIA
- Patients with genetic diagnosis of NLRC4-MAS mutation or XIAP deficiency (caused by BIRC4 gene mutation) as confirmed by analysis performed at the central genetics laboratory. If possible, flow cytometry assay will be performed in parallel to confirm diagnosis of XIAP deficiency. (Note: Previous flow cytometry assay results will be permitted for confirmation of XIAP deficiency diagnosis.)
- Patients with XIAP deficiency and a previous bone marrow transplantation are allowed, if they show evidence of primary or secondary graft failure, or failure to achieve phenotypic correction with evidence of XIAP-related disease recurrence or clinically significant mixed chimerism.
- Ferritin ≥ 500 ng/mL or persistent elevation of CRP ≥ 2x ULN and mAIDAI ≥4
- Patients receiving corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs) or disease modifying anti-rheumatic drugs (DMARDs), and/or IL-1 blockade with insufficient response to treatment upon enrollment are allowed into the study. Patients not receiving any of these treatments before start of therapy are also allowed.
- Women of childbearing potential with negative urine pregnancy test (UPT) at all visits (if UPT is positive, a blood test for human chorionic gonadotropin (hCG) to be performed) and who agree to follow highly effective birth control recommendations during the study and until 1 month after the end of the treatment. Birth control methods considered highly effective are: combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation, progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), bilateral tubal occlusion, vasectomized partner or sexual abstinence. In each case of delayed menstrual period (over one month between menstruations, confirmation of absence of pregnancy is strongly recommended. This recommendation also applies to women of childbearing potential with infrequent or irregular menstrual cycles. A post-study contraception duration of 4 weeks is recommended taking into account the median half-life of Tadekinig alfa of almost 40h and 5 half-lives representing a duration of 200 hours.
EXCLUSION CRITERIA
- Patients with life-threatening co-morbidities not associated with the underlying NLRC4-mutation or XIAP deficiency
- Positive test for or prior history of HIV, Hepatitis B or Hepatitis C (serology)
- Presence of active infections or a history of pulmonary TB infection with or without documented adequate therapy
- Presence of life threatening infections
- Oncologic causes of symptoms; current or previous history of malignancy
- Presence of CNS manifestations (i.e. seizures, altered mental status, signs of increased intracranial pressure, chronic papilledema, loss of vision, other sensorineural deficiencies, etc.)
- Patients suffering from biallelic mutations in any of the following genes: PRF1/Perforin, UNC13D/Munc 13-4, STX11/Syntaxin11, STXB2/Munc 18-2, RAB27A/Rab27a (Griscelli syndrome type 2), LYST (Chediak-Higashi syndrome), AP3B1, ADTB3A, HPS2 mutations (Hermansky-Pudlak syndrome 2) and X-linked lymphoproliferative syndrome (XLP)-1 with SH2D1A mutation
- Patients who are pregnant or nursing, women of childbearing potential who are unwilling to use highly effective birth control methods (see definition in Inclusion Criteria above) through 4 weeks after the end of their participation in the study
- Concomitant use of immunosuppression therapies excluded by the protocol. Note: NSAIDs, glucocorticoids, cyclosporine, tacrolimus, and IL-1 inhibitors (anakinra, canakinumab, or rilonacept, or others) are allowed
- Patients and/or parents (or legal representative, if applicable) not willing to sign assent/informed consent
- Hypersensitivity to the active substance or one of the excipients of the investigational product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tadekinig alfa
Patients that showed response to treatment in the SAOL phase will receive Tadekinig alfa for up to 16 weeks.
|
Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line.
Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients.
It is available in a concentration of 20mg/0.5mL.
Other Names:
|
Placebo Comparator: 0.9% sodium chloride
Patients that showed response to treatment in the SAOL phase will receive placebo comparator for up to 16 weeks.
|
To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevention of flares
Time Frame: 16 weeks
|
The primary outcome measure is the time to first occurrence of disease reactivation during the 16-week RW phase. Method of assessment : Biomarkers (CRP / Ferritin) and clinical manifestations of systemic inflammation and end-organ damage. |
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Best response
Time Frame: 18 weeks
|
Best response to therapy during the SAOL phase including either complete response, partial response or disease improvement Method of assessment : Biomarkers (CRP / Ferritin) and clinical manifestations of systemic inflammation and end-organ damage.
|
18 weeks
|
Duration of response
Time Frame: 18 weeks
|
Duration of response to therapy during the SAOL phase
|
18 weeks
|
Intensity of flares
Time Frame: 16 weeks
|
Intensity of flares (defined by the level of activity given by the mAIDAI)
|
16 weeks
|
Serum CRP, Serum Ferritin
Time Frame: 34 weeks
|
Laboratory measure ug/mL for CRP, and ng/mL for Ferritin
|
34 weeks
|
Improvement of fevers, improvement of hepato/splenomegaly
Time Frame: 34 weeks
|
Clinical assessments if present at Baseline
|
34 weeks
|
Improvement in serum albumin and liver transaminases, anemia and/or platelet count
Time Frame: 34 weeks
|
Laboratory measures if present at Baseline
|
34 weeks
|
Hospital length of stay
Time Frame: 34 weeks
|
Length of hospitalisation
|
34 weeks
|
Change in Physician Global Assessment (PGA)
Time Frame: 34 weeks
|
Change from RW baseline to EOS in the PGA symptom severity score
|
34 weeks
|
Quality of life
Time Frame: 34 weeks
|
Change of patient's/Caregiver's qualitative evaluation of health status during the study duration
|
34 weeks
|
Presence of skin rash - evolution if present at Baseline or appearance during the study
Time Frame: 34 weeks
|
Measured by the local tolerability index
|
34 weeks
|
Tolerance to oral/enteral nutrition for hospitalized patients if intestinal dysfunction was present at Baseline
Time Frame: 34 weeks
|
Measured by the kcal per day
|
34 weeks
|
Improvement of stool output for hospitalized patients if intestinal dysfunction was present at Baseline
Time Frame: 34 weeks
|
mL per 24hours
|
34 weeks
|
Adverse events will be reported
Time Frame: 34 weeks (SAOL + RW phases)
|
Including AESI (Adverse Events of Special Interest)
|
34 weeks (SAOL + RW phases)
|
Physical examination findings and vital signs
Time Frame: 34 weeks (SAOL + RW phases)
|
Clinically significant changes from Baseline
|
34 weeks (SAOL + RW phases)
|
Laboratory assessments
Time Frame: 34 weeks (SAOL + RW phases)
|
Including clinically significant changes from Baseline in hematology with platelet counts, CRP, ESR, ferritin, fibrinogen, D-dimer, liver enzymes.
(Followed until resolution)
|
34 weeks (SAOL + RW phases)
|
Immunogenicity evaluation
Time Frame: 34 weeks (SAOL + RW phases)
|
Generation of anti-recombinant human IL-18BP (anti-rhIL-18BP) antibodies
|
34 weeks (SAOL + RW phases)
|
Local tolerability at the injection site
Time Frame: 34 weeks (SAOL + RW phases)
|
Evaluated by a standardized assessment
|
34 weeks (SAOL + RW phases)
|
Disease reactivation rate
Time Frame: 18 weeks
|
Disease reactivation rate for individual subjects (number of disease reactivations experienced per week while each subject is on the study treatment during the SAOL phase)
|
18 weeks
|
Treatment failures
Time Frame: 34 weeks
|
Treatment failures (i.e.
patients who experience at least one disease reactivation)
|
34 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response to therapy
Time Frame: 18 weeks
|
Response to therapy in the SAOL phase from Week 10 onwards
|
18 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ed M Behrens, MD, Children Hospital of Philadelphia
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 21, 2017
Primary Completion (Actual)
October 31, 2023
Study Completion (Actual)
November 2, 2023
Study Registration Dates
First Submitted
February 28, 2017
First Submitted That Met QC Criteria
April 10, 2017
First Posted (Actual)
April 14, 2017
Study Record Updates
Last Update Posted (Actual)
February 2, 2024
Last Update Submitted That Met QC Criteria
February 1, 2024
Last Verified
November 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NLRC4/XIAP.2016.001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
This information will be provided soon
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on NLRC4-MAS
-
AB2 Bio Ltd.Active, not recruitingNLRC4-MAS | XIAP DeficiencyUnited States, Canada, Germany
-
National Institute of Allergy and Infectious Diseases...RecruitingDIRA | NLRC4-MAS | NOMID | SAVI | CANDLEUnited States
-
Gunnar LachmannCompletedHemophagocytic Lymphohistiocytosis (HLH) | Macrophage Activation Syndrome (MAS) | Hemophagocytic Syndromes
-
Novartis PharmaceuticalsRecruitingNLRC4-GOF, AIFEC (Autoinflammation With Infantile Enterocolitis), XIAP Deficiency, CDC42 MutationsSpain, France, United States, Canada, Japan, United Kingdom, Turkey, Czechia, Italy
-
Swedish Orphan BiovitrumRecruitingSystemic Lupus Erythematosus | Macrophage Activation Syndrome | Still Disease | Secondary Hemophagocytic Lymphohistiocytosis | SJIA | AOSD | MASUnited States, Belgium, Italy, Netherlands, United Kingdom, China, France, Spain, Czechia, Canada, Sweden, Japan, Germany, Poland
Clinical Trials on Tadekinig alfa
-
University of PennsylvaniaRecruitingCRS - Cytokine Release Syndrome | HLHUnited States
-
AB2 Bio Ltd.Active, not recruitingNLRC4-MAS | XIAP DeficiencyUnited States, Canada, Germany
-
AB2 Bio Ltd.CompletedStill's Disease, Adult-OnsetGermany, France, Switzerland
-
ShireCompleted
-
Jonsson Comprehensive Cancer CenterAmgenCompletedLymphoma | Leukemia | Anemia | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Lymphoproliferative Disorder | Precancerous/Nonmalignant ConditionUnited States
-
Johnson & Johnson Pharmaceutical Research & Development...Ortho Biotech Clinical Affairs, L.L.C.TerminatedNeoplasms | Cancer | AnemiaUnited States
-
Philogen S.p.A.RecruitingCarcinoma, Basal Cell | Carcinoma, Cutaneous Squamous CellGermany, Poland, Switzerland
-
Novo Nordisk A/SCompletedCongenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With InhibitorsTaiwan, United Kingdom, Thailand, Serbia, Croatia, Italy, Poland, Romania, Hungary, Malaysia, United States, Austria, Brazil, Greece, Japan, Puerto Rico, Russian Federation, South Africa, Turkey
-
University of California, San FranciscoDuke UniversityRecruitingWolman Disease | MPS IVA | Pompe Disease Infantile-Onset | Gaucher Disease, Type 2 | MPS VI | MPS I | Gaucher Disease, Type 3 | MPS II | Mps VIIUnited States